Clicky

REGENXBIO Inc(RB0) News

Date Title
Jul 24 REGENXBIO Inc. (RGNX): A Bull Case Theory
Jul 18 REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company
Jul 10 REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
Jun 5 REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Jun 2 REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
Apr 22 Trump’s FDA Sends a Bullish Signal to Biotech
Mar 14 Q4 2024 Regenxbio Inc Earnings Call
Mar 14 Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
Mar 13 Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Mar 13 Regenxbio: Q4 Earnings Snapshot
Mar 13 REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Mar 10 REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 20 Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth